TradingKey

Más Datos de Biogen Inc Compañía

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Información de la empresa

Símbolo de cotizaciónBIIB

Nombre de la empresaBiogen Inc

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoMr. Christopher A. (Chris) Viehbacher

Número de empleados7605

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 17

Dirección225 Binney Street

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02142

Teléfono17814642000

Sitio Webhttps://www.biogen.com/

Símbolo de cotizaciónBIIB

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoMr. Christopher A. (Chris) Viehbacher

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.43K

-41.22%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

Por regiónUSD

Nombre

Ganancia

Proporción

Rest of World

972.70M

40.01%

United States

786.80M

32.37%

United states-Revenues from anti-CD20 therapeutic

378.20M

15.56%

Rest of World-Other revenues

293.30M

12.06%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

Estadísticas de accionistas

Actualizado: sáb., 17 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.87%

BlackRock Institutional Trust Company, N.A.

5.93%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.39%

Accionistas

Proporción

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.87%

BlackRock Institutional Trust Company, N.A.

5.93%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.39%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

52.07%

Investment Advisor/Hedge Fund

25.74%

Hedge Fund

6.51%

Research Firm

2.41%

Pension Fund

2.38%

Bank and Trust

1.80%

Sovereign Wealth Fund

1.64%

Individual Investor

0.17%

Family Office

0.09%

Other

7.19%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

2069

136.06M

92.85%

-10.86M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

16.96M

11.57%

+279.20K

+1.67%

Mar 31, 2025

PRIMECAP Management Company

15.94M

10.88%

-102.95K

-0.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.70M

5.94%

+106.24K

+1.24%

Mar 31, 2025

State Street Global Advisors (US)

7.40M

5.05%

-1.34K

-0.02%

Mar 31, 2025

Wellington Management Company, LLP

4.67M

3.19%

-258.29K

-5.24%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.85M

2.63%

+151.39K

+4.10%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

3.03M

2.07%

-8.46K

-0.28%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

2.66M

1.82%

-439.50K

-14.18%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Invesco Capital Management LLC

2.01M

1.37%

+124.81K

+6.62%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

iShares Neuroscience and Healthcare ETF

4.14%

First Trust NASDAQ Pharmaceuticals ETF

3.61%

VanEck Biotech ETF

3.44%

First Trust NYSE Arca Biotechnology Index Fund

3.43%

Tema Neuroscience and Mental Health ETF

3.35%

Invesco Pharmaceuticals ETF

2.65%

SPDR S&P Biotech ETF

2.3%

First Trust Health Care Alphadex Fund

2.09%

ProShares Ultra Nasdaq Biotechnology

2.05%

Invesco Nasdaq Biotechnology ETF

2.05%

iShares Neuroscience and Healthcare ETF

Proporción4.14%

First Trust NASDAQ Pharmaceuticals ETF

Proporción3.61%

VanEck Biotech ETF

Proporción3.44%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.43%

Tema Neuroscience and Mental Health ETF

Proporción3.35%

Invesco Pharmaceuticals ETF

Proporción2.65%

SPDR S&P Biotech ETF

Proporción2.3%

First Trust Health Care Alphadex Fund

Proporción2.09%

ProShares Ultra Nasdaq Biotechnology

Proporción2.05%

Invesco Nasdaq Biotechnology ETF

Proporción2.05%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Biogen Inc

130.680USD

Biogen Inc

130.680

Descripción general

Compañía

Finanzas